Result of AGM

RNS Number : 7742A
hVIVO plc
31 May 2019
 

HVIVO PLC

("hVIVO" or the "Company")

 

Result of Annual General Meeting

 

London, UK, 31 May 2019: hVIVO plc (AIM: HVO), an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, announces that, all resolutions proposed at its Annual General Meeting, held at 10.00am on 30 May 2019, were duly passed.

 

 

 

For further information please contact:

 

hVIVO plc

 

Trevor Phillips (Executive Chairman)

+44 207 756 1300

Fleur Wood (EVP, Investor Relations & Communications)

 

 

 

Numis Securities Limited

 +44 207 260 1000

Freddie Barnfield (Nominated Adviser)

 

James Black / Michael Burke (Corporate Broking)

 

 

 

 

FTI Consulting

 

Simon Conway / Victoria Foster Mitchell

+44 203 727 1000

 

 

 

Notes to Editors:

hVIVO plc ("hVIVO") is pioneering a human-based clinical trial platform to accelerate drug and vaccine development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV, HRV and respiratory indications, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies and inoculated over 2500 volunteers.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGCKDDBKBKDFPN

Companies

Hvivo (HVO)
UK 100

Latest directors dealings